- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06278532
Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
Validation of the Lithuanian Version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and the Schizophrenia Cognition Rating Scale
Study Overview
Status
Conditions
Detailed Description
This scale validation study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale Schizophrenia Cognition Rating Scale in the Lithuanian sample. The main aim of this study is:
• to evaluate the convergent and discriminant validity of Lithuanian versions of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale.
Participants will be evaluated using the Positive and Negative Symptoms Scale (PANSS), Montgomery Asberg Depression Rating Scale (MADRS), Montreal Cognitive Assessment (MoCA) test, Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale.
To discern the discriminant validity of the Brief Negative Symptoms Scale for negative symptoms, results from the Brief Negative Symptoms Scale will be compared to results from the positive and general subscale of the Positive and Negative Symptoms Scale and the Montgomery Asperger Depression Rating Scale. To discern the convergent validity of the Brief Negative Symptoms Scale for negative symptoms, results from the Brief Negative Symptoms Scale will be compared to the results from the negative subscale of the Positive and Negative Symptoms Scale and the Self-evaluation of Negative Symptoms scale.
To discern the discriminant validity of the Calgary Depression Scale for Schizophrenia for depressive symptoms of schizophrenia, results obtained from the Calgary Depression Scale for Schizophrenia will be compared to results obtained from the Positive and Negative Symptoms Scale and the Self-evaluation of Negative Symptoms scale. To check the convergent validity of the Calgary Depression Scale for Schizophrenia, results obtained from the Calgary Depression Scale for Schizophrenia will be compared to results obtained from the Montgomery Asperger Depression Rating Scale.
Finally, to check the discriminant validity of the Schizophrenia Cognition Rating Scale, results obtained from the Schizophrenia Cognition Rating Scale will be compared to results obtained from the Montgomery Asperger Depression Rating Scale and the Positive and Negative Symptoms Scale. In contrast, to prevent convergent validity, results obtained from the Schizophrenia Cognition Rating Scale will be compared to results obtained from the Montreal Cognitive Assessment test.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jonas Montvidas, MD
- Phone Number: +37066240919
- Email: jonas.montvidas@lsmu.lt
Study Contact Backup
- Name: Algirdas Musneckis, MD
- Phone Number: +37061378748
- Email: algirdas.musneckis@kaunoklinikos.lt
Study Locations
-
-
-
Kaunas, Lithuania, LT-50161
- Recruiting
- Lithuanian University of Health Sciences Hospital Kaunas Clinics
-
Contact:
- Jonas Montvidas
- Phone Number: +37066240919
- Email: jonas.montvidas@lsmu.lt
-
Contact:
- Eimantas Zauka
- Phone Number: +37069220076
- Email: eimantas.zauka@kaunoklinikos.lt
-
Kaunas, Lithuania, LT-53137
- Recruiting
- Jonas Montvidas
-
Contact:
- Jonas Montvidas
- Phone Number: +37066240919
- Email: jonas.montvidas@lsmu.lt
-
Contact:
- Algirdas Musneckis
- Phone Number: +37061378748
- Email: algirdas.musneckis@kaunoklinikos.lt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- age 18 - 65 years old;
- Diagnosis of F20, F25 or F21 according to ICD-10;
- Signed informed consent form.
Exclusion Criteria:
- Age younger than 18 or older than 65 years old;
- Did not sign the informed consent form;
- Legally inactive person
- Patients with a comorbid or primary diagnosis of mental retardation according to ICD-10 (F70 - F79);
- Patients with a comorbid or primary diagnosis of mental and behavioural disorders due to psychoactive substance use (F10 - F19)
- Patients with a comorbid of primary diagnosis of organic, including symptomatic, mental disorders (F00 - F09)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validated Lithuanian version of the Brief Negative Symptoms Scale.
Time Frame: Day 1
|
Patients will be evaluated using the Lithuanian version of the Brief Negative Symptoms Scale (score 0 - 78; a greater score means more pronounced negative symptoms) once during the inpatient treatment.
The results will be compared with the Positive and Negative Symptoms Scale score (0 - 210; a greater score means more pronounced symptoms of schizophrenia), Montgomery Asperger Depression Scale (Score 0 - 60; a greater score means greater symptoms of depression), Self-evaluation of Negative Symptoms Scale (score 0 - 40; greater score means more pronounced negative symptoms), and Montreal Cognitive Assessment Test (score 0 - 31; a greater score means better cognitive functions).
Convergent and divergent validities will be calculated for each validated instrument by calculating correlations.
|
Day 1
|
Validated Lithuanian version of the Calgary Depression Scale for Schizophrenia.
Time Frame: Day 1
|
Patients will be evaluated using the Lithuanian version of the Calgary Depression Scale for Schizophrenia (score 0 - 27; a greater score means greater depression) once during the inpatient treatment, and the results will be compared with results from the Positive and Negative Symptoms Scale (score 0 - 210, greater score means more pronounced symptoms of schizophrenia), Montgomery Asperger Depression Scale (Score 0 - 60; greater score means greater symptoms of depression), and Self-evaluation of Negative Symptoms Scale (score 0 - 40; greater score means more pronounced negative symptoms).
Convergent and divergent validities will be calculated for each validated instrument by calculating correlations.
|
Day 1
|
Validated Lithuanian version of the Schizophrenia Cognition Rating Scale.
Time Frame: Day 1
|
Patients will be evaluated using the Lithuanian version of the Schizophrenia Cognition Rating Scale (score 0 - 80; a greater score means worse cognitive functions; global functioning score 1 - 10 with a greater score meaning worse functioning) once during the inpatient treatment, and the results will be compared with results from the Montreal Cognitive Assessment Test (score 0 - 31; a greater score means better cognitive functions).
Convergent and divergent validities will be calculated for each validated instrument by calculating correlations.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between negative symptoms and cognitive deficits of schizophrenia
Time Frame: Day 1
|
Correlation between negative symptoms evaluated with second-generation negative symptoms assessment tools (Brief Negative Symptoms Scale (score 0 - 78; a greater score means more pronounced negative symptoms) and Self-evaluation of Negative Symptoms scale (score 0 - 40; greater score means more pronounced negative symptoms) and Schizophrenia Cognition Rating Scale (score 0 - 80; a greater score means worse cognitive functions; global functioning score 1 - 10 with a greater score meaning worse functioning).
Correlations between specific subscales of the Brief Negative Symptoms Scale, the Self-evaluation of Negative Symptoms Scale, and the Schizophrenia Cognition Rating Scale will be calculated.
We will check for differences in correlation between different ages, education, duration of disease groups, and sexes.
|
Day 1
|
Correlation between depressive symptoms and cognitive deficits of schizophrenia
Time Frame: Day 1
|
Correlation between depressive symptoms evaluated with the Calgary Depression Scale for Schizophrenia (score 0 - 27; a greater score means greater depression) and Schizophrenia Cognition Rating Scale (score 0 - 80; a greater score means worse cognitive functions; global functioning score 1 - 10 with a greater score meaning worse functioning).
Correlations between specific items of the Calgary Depression Scale for Schizophrenia and the Schizophrenia Cognition Rating Scale will be calculated.
We will check for differences in correlation between different ages, education, duration of disease groups, and sexes.
|
Day 1
|
Correlation between negative symptoms, cognitive deficits, depressive symptoms of schizophrenia and health-related quality of life
Time Frame: Day 1
|
Correlation between results obtained from the Brief Negative Symptoms Scale score 0 - 78; a greater score means more pronounced negative symptoms), Self-evaluation of Negative Symptoms Scale (score 0 - 40; a greater score means more pronounced negative symptoms), Calgary Depression Scale for Schizophrenia (score 0 - 27; a greater score means greater depression), and the Schizophrenia Cognition Rating Scale (score 0 - 80; a greater score means worse cognitive functions; global functioning score 1 - 10 with a greater score meaning worse functioning) with results about the health-related quality of life of patients with schizophrenia evaluated with the 36-Item Short Form Survey (8 subscores scored from 0 percent to 100 percent, with more percents meaning better health-related quality of life) will be calculated.
We will check for differences in correlation between different ages, education, duration of disease groups, and sexes.
|
Day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: Virginija Adomaitienė, Prof., Lithuanian University of Health Sciences
Publications and helpful links
General Publications
- Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar;37(2):300-5. doi: 10.1093/schbul/sbq059. Epub 2010 Jun 17.
- Keefe RS, Davis VG, Spagnola NB, Hilt D, Dgetluck N, Ruse S, Patterson TD, Narasimhan M, Harvey PD. Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. Eur Neuropsychopharmacol. 2015 Feb;25(2):176-84. doi: 10.1016/j.euroneuro.2014.06.009. Epub 2014 Jun 28.
- Muller MJ, Brening H, Gensch C, Klinga J, Kienzle B, Muller KM. The Calgary Depression Rating Scale for schizophrenia in a healthy control group: psychometric properties and reference values. J Affect Disord. 2005 Sep;88(1):69-74. doi: 10.1016/j.jad.2005.04.005.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEGKOG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Brief Negative Symptoms Scale
-
Shalvata Mental Health CenterUnknownHealthy Subjects | Chronic Cannabis UsersIsrael
-
St. Louis UniversityCompletedAnterior Cruciate Ligament ReconstructionUnited States
-
Sormland County Council, SwedenUppsala County Council, Sweden; Västmanland County Council, SwedenRecruiting
-
Bursa City HospitalCompletedCarpal Tunnel Syndrome | Symptoms and SignsTurkey
-
Hospices Civils de LyonRecruiting
-
University of ZurichUnknownPsychological Distress | Relatives | PolytraumaSwitzerland
-
Chang Gung Memorial HospitalUnknown
-
CHU de ReimsUnknownBipolar Disorder, SchizophreniaFrance
-
Mount Sinai Hospital, CanadaHarvard Medical School (HMS and HSDM); Patient-Centered Outcomes Research Institute and other collaboratorsActive, not recruitingPerinatal DepressionUnited States, Canada
-
NHS Greater Glasgow and ClydeBuckinghamshire Healthcare NHS TrustNot yet recruitingSpinal Cord Injuries | Central Neuropathic PainUnited Kingdom